​Top Picks 2018: Sangamo Therapeutics is Expanding Gene Editing

MoneyShow  |

Over the past year, we witnessed the incredible transformation of Sangamo Therapeutics (SGMO) from a Wall Street has-been to a widely respected powerhouse in both gene therapy and gene editing, notes John McCamant, editor The Medical Technology Stock Letter.

In fact, this year it became the first company ever to treat a patient with gene editing technology.

Despite all the hype for other gene editing technologies like CRISPR and TALNS, the firm’s tightly held, widely-patented zinc finger technology (ZFN) has emerged as major player in the exciting fields of gene therapy and gene editing.

Meanwhile, there are two partnerships to come that represent significant catalysts for the company.

While not giving specific dates or deadlines, Sangamo is in talks to form new collaborations with large pharma/biotech companies for both its cellular immuno-oncology (CAR-T) and tau protein/Alzheimer’s disease programs.

Download MoneyShow’s 35th Annual Top Picks Report: The 100 Best Stocks for 2018

In our view, these external programs are not on any investors’ radar screens yet, but the size of the deal(s) will, in our view, be large enough and the partners high-end enough for investors to begin to take notice and add substantially to the stock’s valuation.

Importantly, Sangamo is poised to deliver proof-of-concept data in 2018 from their four clinical-stage programs, hemophilia A, MPS I & II and Beta Thal. Positive data from any of these four programs will also serve as positive stock catalysts as it would help de-risk the other programs.

As a reflection of our growing confidence in both the firm’s technology platform and management’s ability to execute and create significant shareholder value, we recently raised our buy price from $15 to $19. Our target price is $26.

John McCamant is editor The Medical Technology Stock Letter.

Subscribe to John McCamant's The Medical Technology Stock Letter here…

About MoneyShow.com: Founded in 1981, MoneyShow is a privately held financial media company headquartered in Sarasota, Florida. As a global network of investing and trading education, MoneyShow presents an extensive agenda of live and online events that attract over 75,000 investors, traders and financial advisors around the world.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Symbol Name Price Change % Volume
SGMO Sangamo Therapeutics Inc. 11.84 0.00 0.01 149,183 Trade



Symbol Last Price Change % Change






INTERVIEW: CEO Steve Stanulis - Stanulis Films

Equities.com's Sam Mitchell interviewing CEO Steve Stanulis of Stanulis Films.